XML 16 R4.htm IDEA: XBRL DOCUMENT v3.25.2
Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Revenues:        
Clinical treatment programs - US $ 25 $ 50 $ 41 $ 90
Total Revenues 25 50 41 90
Costs and Expenses:        
Production costs 10 8 20 16
Research and development 1,174 1,145 2,254 3,096
General and administrative 1,487 2,591 4,032 6,406
Total Costs and Expenses 2,671 3,744 6,306 9,518
Operating loss (2,646) (3,694) (6,265) (9,428)
Gain (Loss) on investments (9) (85) 18 (177)
Interest and other income 10 2,580 21 2,661
Interest expense and other finance costs (149) (179) (273) (251)
(Loss) on warrant issuance (458) (458)
Net Loss $ (2,794) $ (1,836) $ (6,499) $ (7,653)
Basic loss per share $ (3.68) $ (3.00) $ (8.88) $ (15.00)
Diluted loss per share $ (3.68) $ (3.00) $ (8.88) $ (15.00)
Weighted average shares outstanding basic 759,289 528,374 731,650 511,619
Weighted average shares outstanding diluted 759,289 528,374 731,650 511,619